Estimates show that at least 206.5 million people still require preventive treatment against Chronic schistosomiasis and that the transmission still persist in 78 countries globally with more than 200,000 deaths attributable to the disease and associated tissue pathology annually.
This project investigates the ability of their compounds to ameliorate tissue pathology in experimental murine models of chronic schistosomiasis.
Duration: 2017-2018
Donor/funding programme:
Merck Global Health Institute
Partner:
Frank Brombacher Cytokines and Disease, ICGEB Cape Town, South Africa